Skip to main content
Erschienen in: General Thoracic and Cardiovascular Surgery 2/2023

Open Access 23.08.2022 | Original Article

Impact of accurate diagnosis of interstitial lung diseases on postoperative outcomes in lung cancer

verfasst von: Yoko Azuma, Susumu Sakamoto, Sakae Homma, Atsushi Sano, Takashi Sakai, Satoshi Koezuka, Hajime Otsuka, Naobumi Tochigi, Kazuma Kishi, Akira Iyoda

Erschienen in: General Thoracic and Cardiovascular Surgery | Ausgabe 2/2023

Abstract

Objective

The prognostic impact of interstitial lung disease (ILD) subclassification based on both high-resolution computed tomography (HRCT) scan findings and histopathological findings is unknown.

Methods

We retrospectively analyzed 104 patients who were diagnosed with clinical ILD according to HRCT scan findings and who underwent lung cancer surgery. Via an expert multidisciplinary discussion, we re-classified HRCT scan findings and validated the histopathological patterns of ILDs in lung specimens.

Results

There were several mismatches between HRCT scan findings and histological patterns. Moreover, 87 (83.7%) and 6 (5.8%) patients were diagnosed with definitive ILD and pathological non-ILD, respectively. Finally, 82 patients with idiopathic interstitial pneumonias (IIPs) were divided into the idiopathic pulmonary fibrosis (IPF) (n = 61) group and the other group (n = 21). The 5-year overall survival rate of the IPF group was significantly lower than that of the other group (22.8% vs 67.9%; p = 0.011). Sub-classification of IIPs was found to be an independent prognostic factor for overall survival in patients with lung cancer.

Conclusion

An accurate diagnosis of IIPs/IPF according to both HRCT scan findings and histological patterns is important for providing an appropriate treatment among patients with lung cancer who presented with clinical ILD.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Interstitial lung disease (ILD) is characterized by a damaged lung parenchyma associated with different inflammatory and fibrotic patterns [1]. ILD has several subtypes with different pathophysiologies, and its treatment strategies are also diverse [1, 2]. Patients with ILD have a high rate of lung cancer and a high risk of fatal morbidities such as acute exacerbation (AE) of ILD associated with lung cancer treatment [36].
In particular, idiopathic interstitial pneumonias (IIPs) are a group of ILDs defined as diffuse parenchymal diseases with an unknown etiology. Idiopathic pulmonary fibrosis (IPF) is the most common subtype and is correlated with poor prognoses [7]. IPF is defined as a specific type of chronic, progressive fibrosing interstitial pneumonia. Moreover, the condition is associated with the histopathologic and/or radiologic patterns of usual interstitial pneumonia (UIP), and it occurs primarily in older adults, who have the worst prognosis among all ILD subgroups [8]. Therefore, an accurate diagnosis of ILD or its sub-classification is required for an appropriate lung cancer treatment and accurate prognostic prediction.
The American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and Latin American Thoracic Society (ALAT) updated the detailed diagnostic high-resolution computed tomography (HRCT) scan findings and histopathological patterns of IPF in 2018 [1]. However, previous reports about the surgical treatment of lung cancer with ILD have not provided a detailed ILD classification. Similarly, a comparison between the HRCT scan findings and histopathological patterns of IPF based on the 2018 guidelines has not been performed.
This study re-evaluated and compared the HRCT scan findings and histopathological patterns based on the 2018 guidelines for IPF in patients with lung cancer who underwent surgical resection and who were clinically suspected with ILD. This study is first report to validate the characteristics and prognosis of patients after surgery based on the ILD and IIP classifications in patients with lung cancer.

Methods

The Ethics Committee of Toho University Omori Medical Center approved this retrospective study (M20122) on August 28, 2020. A written informed consent or opt-out consent was obtained from all patients.

Study design and population

Data were initially obtained from patients with lung cancer who had undergone pulmonary resection at Toho University Hospital between January 2004 and December 2020. We included 104 patients diagnosed with ILD based on clinical data and radiographic images. The diagnostic criteria have been selected based on the examination period [1, 9, 10].

Diagnostic criteria for patients with clinical ILDs

Figure 1a shows the diagnosis and classification of patients. We re-classified the HRCT scan findings and validated the histopathological patterns of ILDs in lung specimens based on the latest 2018 diagnostic criteria by the ATS, ERS, JRS, and ALAT [1]. The diagnostic classification of ILDs was made via an expert multidisciplinary discussion between pulmonologists, thoracic pathologists, and radiologists. First, patients were divided into four subgroups according to HRCT pattern. Definitive ILD was defined as the presence of UIP pattern. Next, the histopathological pattern of patients with patterns other than UIP on HRCT scan was validated by assessing lung specimens. The patients were then divided into three groups: definitive ILD, pathological non-ILD, lack of histopathological findings associated with ILDs, and unevaluable, which is associated with histopathological patterns due to the excision range or lung specimen condition.
According to clinical data, patients diagnosed with definitive ILD were divided as follows: ILD with a known cause and IIPs. Finally, based on HRCT scan findings and histopathological patterns according to the 2018 IPF diagnostic criteria, patients with IIPs were divided into four groups, which are as follows [1]: IPF, IPF likely, indeterminate IPF, and non-IPF.

Diagnostic criteria for airspace enlargement with fibrosis in lung specimens

The histopathological findings of airspace enlargement with fibrosis (AEF) were based on a previous report [11]. They are as follows: (1) fibrous interstitium with structural remodeling, (2) emphysematous change, (3) frequent bronchiolocentric location, and (4) absence of fibroblastic foci.

Definition of AE

AE was defined according to the International Working Group Report [12] and the Japanese Respiratory Society [13] guidelines. Postoperative AE was defined as complications that developed within 1 month after surgery.

Statistical analysis

The two groups were compared using the student’s t-test for variables with a normal distribution or the Mann–Whitney U test for variables with a non-normal distribution. Survival curves were prepared using the Kaplan–Meier method, and a univariate comparison was performed using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model. All statistical analyses were performed using JMP version 14.0 (SAS Institute Inc., Cary, NC, the USA).

Results

This study enrolled 104 patients with clinical ILD, including those suspected with the condition and those who underwent surgical resection for lung cancer. Supplementary Table 1 shows the characteristics of all patients. The mean age of the patients was 71.2 years, and majority were men and had a history of smoking. In total, 79 (76.0%) patients underwent lobectomy. The most common histological type of lung cancer was squamous cell carcinoma (51.0%), and 54 (51.9%) patients were diagnosed with pathological stage 1 disease. On HRCT, 48 (46.2%) patients presented with a UIP pattern, 24 (23.1%) with a probable UIP pattern, 25 (24.0%) with an indeterminate UIP pattern, and 7 (6.7%) with an alternative diagnosis pattern.

Mismatch between HRCT scan findings and histopathological patterns

We compared the HRCT scan findings and the histopathological patterns of ILDs in patients with patterns other UIP on HRCT scan using evaluable resected lung specimens (n = 45). The lung specimens of 11 patients were not suitable for the evaluation of ILDs because their specimens did not include sufficient fibrotic or noncancerous areas. Most patients (90.9%) underwent surgery of the upper lung lobe.
Figure 1b depicts the percentage of histopathological patterns for each HRCT scan finding. Patients with an alternative diagnosis on HRCT scan did not exhibit a histopathological UIP pattern. Patients with indeterminate UIP pattern on HRCT scan presented with all histopathological patterns at different proportions. Notably, some patients without histopathological characteristics of ILD presented with indeterminate UIP or an alternative diagnosis pattern on HRCT scan. The lung specimens showed pathological AEF among, and patients with this finding were included in the pathological non-ILD group (n = 6).

Similarities and differences in HRCT scan and lung specimen findings between patients diagnosed with IIP and those with pathological non-ILD

We compared the HRCT scan findings and histopathological patterns between patients diagnosed with IIP and those with pathological non-ILD, as shown in Fig. 2, respectively. Figure 2a shows the UIP pattern on HRCT scan image (presence of honeycombing with sub-pleural and basal predominance). Furthermore, histopathological findings including dense fibrosis with architectural distortion in the form of honeycomb change (Fig. 2b), predominant sub-pleural and para-septal distribution of fibrosis (Fig. 2c), and presence of fibroblast foci (Fig. 2d) were the characteristics of a typical UIP pattern. In contrast, a patient diagnosed with pathological non-ILD presented with multiple thin-walled cysts in the lower lung lobe, which is referred to as the indeterminate UIP pattern on HRCT scan (Fig. 2e). Moreover, this patient exhibited the characteristic histopathological findings of AEF: mild fibrous interstitium and emphysematous change without fibroblastic foci (Fig. 2f) and fibrous wall of bronchiolocentric cysts (Figs. 2g , h). Five (83.3%) patients in the pathological non-ILD group had AEF.

Clinicopathological characteristics and prognoses between the IIP and other groups

Patients diagnosed with definitive ILD according to HRCT scan findings and histopathological patterns were classified into the IIP (n = 82) and ILD with a known cause (n = 5) groups. To assess the prognostic impact of IIP diagnosis, we compared the characteristics of patients and postoperative prognoses between the IIP and other groups. Table 1 shows the characteristics of the two groups.
Table 1
Characteristics between the IIP and other groups
 
IIP
(n = 82)
Pathological non-ILD
(n = 6)
p
value*
ILD with a known cause
(n = 5)
p
value**
Male sex
73 (89.0)
4 (66.7)
0.110
0
 < 0.001
Smoking history, yes
79 (96.3)
6 (100)
0.634
2 (40.0)
 < 0.001
Tobacco, pack-years
50.7 ± 32.8
69.4 ± 34.2
0.183
13.4 ± 21.0
0.014
KL-6 level (U/mL)
641.4 ± 371.7
521.3 ± 298.3
0.442
916.2 ± 443.1
0.116
SP-D level (ng/mL)
150.1 ± 93.5
106.9 ± 64.2
0.271
129.8 ± 38.7
0.632
Pulmonary function
     
 VC%pred (%)
98.6 ± 18.6
108.1 ± 22.4
0.235
101.8 ± 20.3
0.708
 DLco%pred (%)
73.8 ± 20.7
72.0 ± 28.8
0.842
61.9 ± 22.5
0.216
 FEV1/FVC (%)
75.5 ± 8.4
60.3 ± 8.1
 < 0.001
78.8 ± 7.9
0.396
HRCT pattern
  
 < 0.001
 
 < 0.001
 UIP
47 (57.3)
0
 
1 (20.0)
 
 Probable UIP
18 (22.0)
0
 
0
 
 Indeterminate UIP
13 (15.9)
6 (100)
 
1 (20.0)
 
 Alternative diagnosis
4 (4.9)
0
 
3 (60.0)
 
Surgical procedure
  
0.569
 
0.707
 Pneumonectomy
1 (1.2)
0
 
0
 
 Lobectomy
61 (74.4)
6 (100)
 
3 (60.0)
 
 Segmentectomy
4 (4.9)
0
 
0
 
 Partial resection
16 (19.5)
0
 
2 (40.0)
 
Clinical staging
  
0.684
 
0.368
 I
41 (50.0)
2 (33.3)
 
4 (80.0)
 
 II
24 (29.3)
2 (33.3)
 
1 (20.0)
 
 III
17 (20.7)
2 (33.3)
 
0
 
Pathologic staging
  
0.425
 
0.516
 I
41 (50.0)
2 (33.3)
 
4 (80.0)
 
 II
17 (20.7)
3 (50.0)
 
1 (20.0)
 
 III
22 (26.8)
1 (16.7)
 
0
 
 IV
2 (2.4)
0
 
0
 
AE from any cause
24 (29.3)
0
0.120
1 (20.0)
0.657
 Postoperative AE
13 (15.9)
0
0.291
0
0.334
Adjuvant therapy
  
0.906
 
0.838
 Carboplatin-based
8 (9.8)
1 (16.7)
 
0
 
 Cisplatin-based
1 (1.2)
0
 
0
 
 Other
3 (3.7)
0
 
0
 
Data were presented as n (%) or mean ± SD. IIP: idiopathic interstitial pneumonia, ILD: interstitial lung disease.
*Significance of IIP vs non-ILD.
**Significance of IIP vs ILD with a known cause
KL-6: Krebs von Den Lungen-6, SP-D: pulmonary surfactant protein-D, VC%pred: percentage of predicted vital capacity, DLco%pred: percentage of predicted diffusing capacity of the lungs for carbon monoxide, FEV1: forced expiratory volume in 1 s, FVC: forced vital capacity, PaO2: partial pressure of oxygen, HRCT: high-resolution computed tomography, UIP: usual interstitial pneumonia, AE: acute exacerbation
The pathological non-ILD group had a significantly lower forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) ratio at the initial visit than the IIP group (p < 0.001). On HRCT scan, all patients in the pathological non-ILD group had an indeterminate UIP pattern. There was a significant difference in HRCT patterns between the IIP and pathological non-ILD groups (p < 0.001). In the IIP group, 24 (29.3%) patients developed AE. Among them, 13 (15.9%) had AEs postoperatively. By contrast, patients with pathological non-ILD did not develop AEs during the study period.
The sub-classifications were microscopic polyangiitis-associated ILD in three and collagen vascular disease-associated ILD in two patients in group with ILD with a known cause. The proportion of women and never smokers was significantly higher in patients with ILD with a known cause than those with IIP (p < 0.001). In total, 13 (15.9%) patients in the IIP group developed postoperative AEs, but none in the ILD with a known cause group.
Patients in the pathological non-ILD and ILD with a known cause groups had a longer 5-year overall survival rate (OS) and disease-free survival rate (DFS) than the IIP group (p = 0.048, p = 0.048) (Fig. 3a , 3b).

Clinicopathologic findings and prognoses between the IPF and other IIP groups

Next, patients with IIP were classified into three groups according to the 2018 IPF diagnostic guidelines. The groups were as follows: IPF (n = 61), probable IPF or indeterminate IPF (n = 16), and non-IPF (n = 5). The cumulative 5-year OS rates were 22.8% in the IPF group, 63.7% in the likely IPF or indeterminate IPF group, and 83.3% in the non-IPF group. The IPF group had a significantly worse OS than the likely IPF and indeterminate IPF groups (p = 0.023).
Finally, we divided patients with IIP into the IPF (n = 61) and other (n = 21) groups. Table 2 shows the characteristics of patients. The IPF group more commonly presented with AE from any cause than the other group (p = 0.021). Further, the 5-year OS and DFS of all patients with IPF were significantly worse than the other group (22.8% vs 67.9%, p = 0.011, 20.1% vs 67.5%, p = 0.006) (Fig. 3c , 3d). Supplementary Table 2 shows the causes of death in patients with IIP. AE was the most frequent cause of death in the IPF group. Nevertheless, none of patients died from AE in the other group.
Table 2
Characteristics of patients with IIPs
 
Patients with IIP (n = 82)
 
Patients with IPF
Others
p value
n = 61
n = 21
Age
70.7 ± 6.6
71.1 ± 8.0
0.727
Male sex
54 (88.5)
19 (90.5)
0.805
Tobacco, pack-years
49.2 ± 24.8
54.8 ± 48.6
0.495
VC%pred (%)
96.5 ± 20.1
104.6 ± 11.7
0.084
DLco%pred (%)
71.7 ± 21.1
79.8 ± 18.7
0.121
  ≥ 80%
22 (36.1)
11 (52.4)
0.189
  < 80%
39 (63.9)
10 (47.6)
 
KL-6 level (U/mL)
684.1 ± 403.8
527.0 ± 239.3
0.091
GAP staging, I/II
47 (77.0)/14 (23.0)
20 (95.2)/1 (4.8)
0.063
Comorbidities
   
 COPD
20 (32.8)
10 (47.6)
0.224
 Cardiovascular disease
33 (54.1)
12 (57.1)
0.809
 Diabetes mellitus
17 (27.9)
5 (23.8)
0.717
Surgical procedure
  
0.886
 Pneumonectomy
1 (1.6)
0
 
 Lobectomy
46 (75.4)
15 (71.4)
 
 Segmentectomy
3 (4.9)
1 (4.8)
 
 Partial resection
11 (18.0)
5 (23.8)
 
Histology
  
0.235
 Adenocarcinoma
17 (27.9)
11 (52.4)
 
 Squamous cell carcinoma
32 (52.5)
7 (33.3)
 
 Small cell carcinoma
5 (8.2)
1 (4.8)
 
 Others
7 (11.5)
2 (9.5)
 
Clinical staging
  
0.391
 I
30 (49.2)
11 (52.4)
 
 II
20 (32.8)
4 (19.0)
 
 III
11 (18.0)
6 (28.6)
 
Pathologic staging
  
0.665
 I
29 (47.5)
12 (57.1)
 
 II
14 (23.0)
3 (14.3)
 
 III
17 (27.9)
5 (23.8)
 
 IV
1 (1.6)
1 (4.8)
 
AE from any cause
22 (36.1)
2 (9.5)
0.021
 Postoperative AE
12 (19.7)
1 (4.8)
0.286
Adjuvant chemotherapy
  
0.778
 Carboplatin-based
5 (8.2)
3 (14.3)
 
 Cisplatin-based
1 (1.6)
0
 
 Other
2 (3.3)
1 (4.8)
 
Recurrence, present
20 (32.8)
8 (38.1)
0.658
Data were presented as n (%) or mean ± SD; IIP: idiopathic interstitial pneumonia, IPF: idiopathic pulmonary fibrosis, VC%pred: percentage of predicted vital capacity, DLco%pred: percentage of predicted diffusing capacity of the lungs for carbon monoxide, KL-6: Krebs von Den Lungen-6, GAP: gender–age–physiology, COPD: chronic obstructive pulmonary disease, AE: acute exacerbation

Univariate and multivariate analyses of the prognostic factors for OS

Based on the univariate analysis of patients with IIPs, IIP classification, VC%pred, DLco%pred, and clinical stage were the prognostic factors for long-term prognosis. According to the multivariate analysis, IIP classification and clinical stage were considered independent prognostic factors for OS (Supplementary Table 3).

Discussion

This study first revealed that patients with lung cancer diagnosed with clinical ILD and those with pathological non-ILD had different ILD classifications. Histopathological examination confirmed the mismatch between HRCT scan findings and pathological patterns and the prognostic impact of an accurate ILD and IIP sub-classification in patients with lung cancer.
In patients with lung cancer, the coexistence or classification of ILDs has a significant influence on lung cancer treatment and prognosis. Chemotherapy and radiation therapy are correlated with a high incidence of AE (10%–25% and 12.5%, respectively) [46]. Therefore, surgical resection is the only treatment option for lung cancer. However, postoperative patients with ILDs are at risk of AE. Based on a large multi-institutional cohort study of patients with ILD and non-small cell lung cancer who underwent surgery, the incidence of postoperative AE was 9.3%. Moreover, about 43.9% of patients died of this complication [6].
In terms of ILD classifications, patients with IPF have a high incidence of AE associated with lung cancer treatment, and IPF itself is a progressive disease with a poor prognosis. Previous reports showed that 10.7%–23.1% of patients with IPF developed postoperative AE [14, 15] and IPF was a risk factor for AE after chemotherapy [16]. Our data showed that an accurate classification of ILD and IIP affects prognosis after lung cancer surgery.
The diagnosis and classification of ILDs often require a multidisciplinary discussion between pulmonologists, radiologists, and pathologists with experience in the field of interstitial lung diseases [17]. In particular, in patients clinically suspected with IPF with HRCT scan findings, such as probable UIP, indeterminate UIP, and alternative diagnosis, surgical lung biopsy is recommended for the definitive diagnosis of IPF [1]. In fact, this study showed several mismatches between HRCT scan findings and histopathological patterns.
In particular, it is challenging to distinguish UIP from AEF based on HRCT scan findings alone. IPF and AEF are considered smoking-related lung abnormalities, and both often represent a multiple cyst resembling a honeycomb on HRCT scan images among heavy smokers [1821]. By contrast, in most cases, the clinical course of patients with AEF alone is stable [18], and there is no risk of AE. In this study, almost all patients diagnosed with pathological non-ILD presented with AEF and concurrent COPD. Their prognosis was better than that of patients with IIPs, and none developed AE from any cause.
As mentioned above, the definitive diagnosis of lung abnormalities in patients with
lung cancer who were clinically suspected with ILDs has important implications in both lung cancer treatment and ILD management. Extraction of pathological non-ILD patients can allow them to receive the benefits of lung cancer treatment without limitations. By contrast, an early definitive diagnosis of ILDs can facilitate cautious management and provide appropriate interventions with anti-fibrotic drugs or prednisolone. In this study, the lung specimens obtained via upper lobe or partial resection were not eligible for obtaining a pathological ILD diagnosis. When performing surgical procedures, simultaneous surgical lung biopsy at the appropriate site should be considered for the diagnosis of ILD except among patients with a definitive UIP pattern on HRCT scan.
Since surgical treatment is often the only treatment for ILD-related lung cancer, the most effective surgical method should be selected regardless of ILD classification, and cardiopulmonary function and comorbidities should remain criteria for surgical selection. With regard to postoperative adjuvant chemotherapy, patients diagnosed with ILD by imaging or histopathology are at risk of acute exacerbation, regardless of ILD classification, and the indication for adjuvant chemotherapy should be carefully determined. However, in cases such as AEF that are not histologically ILD, postoperative adjuvant chemotherapy should be aggressively considered.
This retrospective study had several limitations and biases. The number of patients with ILD with a known cause or pathological non-ILD was limited.

Conclusion

An accurate, detailed diagnosis of IIP/IPF according to both HRCT scan findings and histopathological patterns is important for providing an appropriate treatment among patients with lung cancer.

Acknowledgements

We thank Dr. Toshimasa Uekusa at Department of Pathology, Labor Health and Welfare Organization Kanto Rosai Hospital for providing histopathological imaging for us.

Declarations

Conflict of interest statement

All authors have no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Chirurgie

Kombi-Abonnement

Mit e.Med Chirurgie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Chirurgie, den Premium-Inhalten der chirurgischen Fachzeitschriften, inklusive einer gedruckten chirurgischen Zeitschrift Ihrer Wahl.

Literatur
1.
Zurück zum Zitat Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer D, et al. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44-e68. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer D, et al. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44-e68.
2.
Zurück zum Zitat Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811–23. CrossRef Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811–23. CrossRef
3.
Zurück zum Zitat Iyoda A, Azuma Y, Sakamoto S, Homma S, Sano A. Surgical treatment for patients with idiopathic pulmonary fibrosis and lung cancer: postoperative acute exacerbation of idiopathic pulmonary fibrosis and outcomes. Surg Today. 2021;52:736–44. CrossRef Iyoda A, Azuma Y, Sakamoto S, Homma S, Sano A. Surgical treatment for patients with idiopathic pulmonary fibrosis and lung cancer: postoperative acute exacerbation of idiopathic pulmonary fibrosis and outcomes. Surg Today. 2021;52:736–44. CrossRef
4.
Zurück zum Zitat Kenmotsu H, Naito T, Mori K, Ko R, Ono A, Wakuda K, et al. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol. 2015;75:521–6. CrossRef Kenmotsu H, Naito T, Mori K, Ko R, Ono A, Wakuda K, et al. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol. 2015;75:521–6. CrossRef
5.
Zurück zum Zitat Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013;82:260–5. CrossRef Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013;82:260–5. CrossRef
6.
Zurück zum Zitat Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2014;147:1604-11.e3. CrossRef Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2014;147:1604-11.e3. CrossRef
7.
Zurück zum Zitat American Thoracic Society, European Respiratory Society, American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304. American Thoracic Society, European Respiratory Society, American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304.
8.
Zurück zum Zitat King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–61. CrossRef King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–61. CrossRef
9.
Zurück zum Zitat American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646–64. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646–64.
10.
Zurück zum Zitat Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. CrossRef Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. CrossRef
11.
Zurück zum Zitat Kawabata Y, Hoshi E, Murai K, Ikeya T, Takahashi N, Saitou Y, et al. Smoking-related changes in the background lung of specimens resected for lung cancer: a semiquantitative study with correlation to postoperative course. Histopathology. 2008;53:707–14. CrossRef Kawabata Y, Hoshi E, Murai K, Ikeya T, Takahashi N, Saitou Y, et al. Smoking-related changes in the background lung of specimens resected for lung cancer: a semiquantitative study with correlation to postoperative course. Histopathology. 2008;53:707–14. CrossRef
12.
Zurück zum Zitat Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194:265–75. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194:265–75.
13.
Zurück zum Zitat The Japanese Respiratory Society, Idiopathic Interstitial Pneumonias: Diagnosis and Treatment, 3rd ed., Nankodo, 2016. The Japanese Respiratory Society, Idiopathic Interstitial Pneumonias: Diagnosis and Treatment, 3rd ed., Nankodo, 2016.
14.
Zurück zum Zitat Saito Y, Kawai Y, Takahashi N, Ikeya T, Murai K, Kawabata Y, et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2011;92:1812–7. CrossRef Saito Y, Kawai Y, Takahashi N, Ikeya T, Murai K, Kawabata Y, et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2011;92:1812–7. CrossRef
16.
Zurück zum Zitat Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol. 2011;6:1242–6. CrossRef Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol. 2011;6:1242–6. CrossRef
17.
Zurück zum Zitat Flaherty KR, King TE Jr, Raghu G, Lynch JP 3rd, Colby TV, Travis WD, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004;170:904–10. CrossRef Flaherty KR, King TE Jr, Raghu G, Lynch JP 3rd, Colby TV, Travis WD, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004;170:904–10. CrossRef
18.
Zurück zum Zitat Katzenstein ALA, Mukhopadhyay S, Zanardi C, Dexter E. Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens. Hum Pathol. 2010;41:316–25. CrossRef Katzenstein ALA, Mukhopadhyay S, Zanardi C, Dexter E. Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens. Hum Pathol. 2010;41:316–25. CrossRef
19.
Zurück zum Zitat Reddy TL, Mayo J, Churg A. Respiratory bronchiolitis with fibrosis. High-resolution computed tomography findings and correlation with pathology. Ann Am Thorac Soc. 2013;10:590–601. Reddy TL, Mayo J, Churg A. Respiratory bronchiolitis with fibrosis. High-resolution computed tomography findings and correlation with pathology. Ann Am Thorac Soc. 2013;10:590–601.
20.
Zurück zum Zitat Iwasawa T, Takemura T, Ogura T. Smoking-related lung abnormalities on computed tomography images: comparison with pathological findings. Jpn J Radiol. 2018;36:165–80. CrossRef Iwasawa T, Takemura T, Ogura T. Smoking-related lung abnormalities on computed tomography images: comparison with pathological findings. Jpn J Radiol. 2018;36:165–80. CrossRef
21.
Zurück zum Zitat Watanabe Y, Kawabata Y, Kanauchi T, Hoshi E, Kurashima K, Koyama S, et al. Multiple, thin-walled cysts are one of the HRCT features of airspace enlargement with fibrosis. Eur J Radiol. 2015;84:986–92. CrossRef Watanabe Y, Kawabata Y, Kanauchi T, Hoshi E, Kurashima K, Koyama S, et al. Multiple, thin-walled cysts are one of the HRCT features of airspace enlargement with fibrosis. Eur J Radiol. 2015;84:986–92. CrossRef
Metadaten
Titel
Impact of accurate diagnosis of interstitial lung diseases on postoperative outcomes in lung cancer
verfasst von
Yoko Azuma
Susumu Sakamoto
Sakae Homma
Atsushi Sano
Takashi Sakai
Satoshi Koezuka
Hajime Otsuka
Naobumi Tochigi
Kazuma Kishi
Akira Iyoda
Publikationsdatum
23.08.2022
Verlag
Springer Nature Singapore
Erschienen in
General Thoracic and Cardiovascular Surgery / Ausgabe 2/2023
Print ISSN: 1863-6705
Elektronische ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-022-01868-6

Weitere Artikel der Ausgabe 2/2023

General Thoracic and Cardiovascular Surgery 2/2023 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.